Lisa Bearman
Acute Care · Baltimore, MDNPI 1306492913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,460 and has fallen 78.9% since, to $309 in 2025. Among acute care clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$470
- Takeda Pharmaceuticals U.S.A., Inc.$278
- GSK$254
- Axsome Therapeutics, Inc.$250
- Harmony Biosciences LLC$148
- Actelion Pharmaceuticals US, Inc.$139
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,657100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 25 | $470 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $278 |
| GSK | 14 | $254 |
| Axsome Therapeutics, Inc. | 9 | $250 |
| Harmony Biosciences LLC | 5 | $148 |
| Actelion Pharmaceuticals US, Inc. | 6 | $139 |
| Regeneron Healthcare Solutions, Inc. | 6 | $132 |
| Sanofi | 5 | $95 |
| Jazz Pharmaceuticals Inc. | 3 | $91 |
| Mylan Specialty L.p. | 4 | $90 |
| Merck | 4 | $81 |
| Novartis | 4 | $80 |
| Grifols USA, LLC | 3 | $63 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $58 |
| Boehringer Ingelheim | 2 | $52 |
| AbbVie | 2 | $51 |
| Tactile Systems Technology Inc | 1 | $43 |
| Vifor Pharma, Inc. | 2 | $42 |
| Radius Health, Inc. | 1 | $27 |
| Incyte Corporation | 1 | $27 |
| Baxter Healthcare | 1 | $27 |
| Seagen Inc. | 1 | $25 |
| KCI USA, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Gilead | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
How this compares
$2,657 in reported general payments places this provider in the 90th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 149 | $138,501 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $26,230 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $20,133 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,129 |
| DuleraMometasone/Formoterol | 20 | $7,472 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $3,277 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,116 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,081 |
| Armodafinil | 16 | $1,328 |
| Azithromycin | 31 | $596 |
| Gabapentin | 20 | $324 |
| Pantoprazole Sodium | 18 | $195 |
| Fluticasone Propionate | 14 | $113 |
| Prednisone | 22 | $77 |
| Trazodone Hcl | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $254 | $164,732194 claims |
| AstraZenecaBreztri Aerosphere | $470 | $20,13320 claims |
| Boehringer IngelheimSpiriva Respimat | $52 | $10,12912 claims |
| MerckDulera | $81 | $7,47220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 502 acute care providers in Maryland.
Other acute care in Baltimore
- Paige GriffithBaltimore$106K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Eleanor DunlapBaltimore$11K
- Lateaqua AlstonBaltimore$9K
- Archana PatelBaltimore$8K
- Tamara HillBaltimore$8K
- Robert GoodfellowBaltimore$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.